Straits Times Index
3,187.39 -7.65 (-0.24%) S&P 500
3,941.48 -32.27 (-0.81%) Dow
31,928.62 +48.38 (+0.15%) Nasdaq
11,264.45 -270.83 (-2.35%) BTC-USD
29,734.50 +452.23 (+1.54%) CMC Crypto 200
662.01 +6.18 (+0.94%)
Exicure, Inc. (XCUR)
Pre-market:
- Business Wire
Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference
CHICAGO, May 17, 2022--Exicure today announced that CEO Matthias Schroff will provide a virtual presentation at the 2022 H.C. Wainwright Global Life Sciences Conference.
- Business Wire
Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress
CHICAGO, May 16, 2022--Exicure today reported financial results for the quarter ended March 31, 2022 and provided an update on its business strategy and corporate progress.
- Business Wire
Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium
CHICAGO, May 10, 2022--Exicure, Inc.® (NASDAQ:XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that it has agreed to sell an aggregate of 26,021,111 shares of its common stock at a purchase price of $0.1937 per share to certain accredited investors in a private placement in public equity ("PIPE") financing. The purch
